Abstract Policies & Exceptions

Confidentiality Policy Exceptions
According to ASCO's Confidentiality Policy, each abstract submitted to an ASCO meeting is confidential from the time of submission until the date and time when ASCO makes the abstract publicly available. Under rare, extenuating circumstances requiring a formal application, abstracts may receive an Exception to ASCO’s Confidentiality Policy. These formal Exceptions require approval by ASCO prior to the information being made public.

The following abstracts have received formal Exceptions to ASCO’s Confidentiality Policy for the 2018 Gastrointestinal Cancers Symposium:

Abstract 5, "RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma," Charles Fuchs, et al.